{"id":54311,"date":"2023-02-28T13:05:32","date_gmt":"2023-02-28T12:05:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/"},"modified":"2023-02-28T13:05:32","modified_gmt":"2023-02-28T12:05:32","slug":"seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/","title":{"rendered":"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc.<\/a> (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update.\n<\/p>\n

<\/a><\/p>\n

\nTo access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4218669. To join the live webcast, please visit the \u201cInvestors and News\u201d section of the Seres website at www.serestherapeutics.com<\/a>.\n<\/p>\n

\nA webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.\n<\/p>\n

\nAbout Seres Therapeutics<\/b>\n<\/p>\n

\nSeres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres\u2019 SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile<\/i> infection and has potential to become a first-in-class oral FDA-approved microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.\n<\/p>\n

\nFor more information, please visit www.serestherapeutics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIR and PR<\/b>
Carlo Tanzi, Ph.D.
\n
ctanzi@serestherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update. To access the conference call, please dial … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54311","6":"format-standard","7":"category-industry"},"yoast_head":"\nSeres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update. To access the conference call, please dial ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-28T12:05:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230228005113\/en\/1722984\/21\/PRESS_RELEASE_LOGO_Seres.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023\",\"datePublished\":\"2023-02-28T12:05:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/\"},\"wordCount\":295,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228005113\\\/en\\\/1722984\\\/21\\\/PRESS_RELEASE_LOGO_Seres.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/\",\"name\":\"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228005113\\\/en\\\/1722984\\\/21\\\/PRESS_RELEASE_LOGO_Seres.jpg\",\"datePublished\":\"2023-02-28T12:05:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228005113\\\/en\\\/1722984\\\/21\\\/PRESS_RELEASE_LOGO_Seres.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230228005113\\\/en\\\/1722984\\\/21\\\/PRESS_RELEASE_LOGO_Seres.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/","og_locale":"en_US","og_type":"article","og_title":"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update. To access the conference call, please dial ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-28T12:05:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230228005113\/en\/1722984\/21\/PRESS_RELEASE_LOGO_Seres.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023","datePublished":"2023-02-28T12:05:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/"},"wordCount":295,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230228005113\/en\/1722984\/21\/PRESS_RELEASE_LOGO_Seres.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/","url":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/","name":"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230228005113\/en\/1722984\/21\/PRESS_RELEASE_LOGO_Seres.jpg","datePublished":"2023-02-28T12:05:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230228005113\/en\/1722984\/21\/PRESS_RELEASE_LOGO_Seres.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230228005113\/en\/1722984\/21\/PRESS_RELEASE_LOGO_Seres.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-host-fourth-quarter-2022-financial-results-and-operational-progress-conference-call-and-webcast-on-march-7-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54311"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54311\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}